![Snehal Naik](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Snehal Naik
Technik-/Wissenschafts-/F&E-Leiter bei
VENTYX BIOSCIENCES, INC.
Profil
Snehal Naik currently holds the position of Chief Development Officer at Equillium, Inc. starting in 2026.
Dr. Naik is also Senior Vice President-Clinical Development at Ventyx Biosciences, Inc. since 2024, with employment at Ventyx Biosciences beginning in 2021.
The education history includes an undergraduate degree from the University of Kentucky and a doctorate from Temple University School of Medicine.
Aktive Positionen von Snehal Naik
| Unternehmen | Position | Beginn |
|---|---|---|
| VENTYX BIOSCIENCES, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.02.2024 |
| EQUILLIUM, INC. | Corporate Officer/Principal | 01.05.2026 |
Ausbildung von Snehal Naik
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
33
Beziehungen ersten Grades
4
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
University of Kentucky
 University of Kentucky Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Temple University School of Medicine
 Temple University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Equillium, Inc.
 Equillium, Inc. BiotechnologyHealth Technology Engages in the development of products for severe immune-inflammatory disorders | Health Technology |
Ventyx Biosciences, Inc.
 Ventyx Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops oral therapies for patients with autoimmune, inflammatory and neurodegenerative diseases | Health Technology |
